Skip to main content
. 2022 May 16;151:113104. doi: 10.1016/j.biopha.2022.113104

Fig. 2.

Fig. 2

SARS-CoV-2 lentiviral pseudovirus entry inhibition assay. Correlation of two independent screens of 774 FDA-approved drugs (A), frequency distribution of the two screens (B), dose response curves of Decitabine (blue) and Trifluoperazine (red) as example for DNA replication inhibitor and dopamine receptor antagonist (C), dose response curves of Docetaxel (green) and Alprostadil (brown) as example for a microtubule polymerization inhibitor and Prostaglandin E1 (D). Data shown in A) and B) are based on singlicates, data shown in C) and D) are based on the average and standard deviation of three independent experiments.